SLRX Overview

Correction of Misinformation: Salarius Pharmaceuticals addresses an error on the S&P CapIQ platform that incorrectly stated the company had been delisted from Nasdaq, confirming that its stock continues to trade under the ticker "SLRX."

Recent Financial Activities: The company completed an $8 million public offering and merged with Decoy Therapeutics, resulting in a combined cash position of approximately $14 million and around 5.9 million shares outstanding.

Focus on Drug Development: Salarius is advancing Decoy's pipeline of peptide conjugate therapeutics, utilizing its IMP3ACT platform, which incorporates AI and machine learning to streamline drug development.

Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future plans and potential risks, emphasizing that actual results may differ from expectations due to various uncertainties.

Penny Stocks to Watch: Leap Therapeutics, Amaze Holdings, and Salarius Pharmaceuticals are highlighted as key penny stocks to monitor on November 13, 2025, based on their Dollar Volume and market activity.

Leap Therapeutics Update: Leap Therapeutics (LPTX) experienced a significant stock price increase of over 368% after announcing plans to expand into digital asset investments and rebranding to "Cypherpunk Technologies" (CYPH).

Amaze Holdings Acquisition: Amaze Holdings (AMZE) saw a nearly 17% drop in stock price despite acquiring The Food Channel's assets for $650,000, aiming to enhance its creator-powered commerce platform.

Salarius Pharmaceuticals Recovery: Salarius Pharmaceuticals (SLRX) had a 17.4% stock price gain following a public offering to raise $7 million for research and debt repayment, reversing a previous 51% drop.